PATH | VRL
Menu

Too Late to Vaccinate? The Incremental Benefits and Cost-Effectiveness of a Delayed Catch-Up Program Using the 4-Valent Human Papillomavirus Vaccine in Norway

This article, published in the Journal of Infectious Diseases, reports on a study to evaluate the benefits and cost-effectiveness of a delayed, one-year female catch-up human papillomavirus (HPV) vaccine program in Norway. The authors found that incremental benefits and cost-effectiveness decreased as the age limit for catch-up increased, but vaccination that provided high-levels of protection in women up to age 26 years with prior HPV exposure was cost-effective. They concluded that HPV vaccination catch-up programs may be warranted, but the cost-effectiveness of vaccinating beyond age 22 years remains uncertain.

Author: Burger EA, Sy S, Nygard M, Kristiansen IS, Kim JJ

Published: 2015

» Visit web page (English)

(Located at jid.oxfordjournals.org)

Citation: Burger EA, Sy S, Nygard M, Kristiansen IS, Kim JJ. Too Late to Vaccinate? The Incremental Benefits and Cost-Effectiveness of a Delayed Catch-Up Program Using the 4-Valent Human Papillomavirus Vaccine in Norway. Journal of Infectious Diseases. 2015;211(2):206-215.

Resource types: Peer-reviewed journal

Diseases/vaccines: Human papillomavirus (HPV)

Topics: Immunization financing, Vaccine safety and performance, Disease/vaccine specific information

Regions: North America and Europe